Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data
BackgroundChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2 are the five common COVID-19 vaccines used in Jakarta. Randomized controlled trials have provided robust evidence of the safety and efficacy profile of these vaccines, but their real-world vaccine effectivene...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2025-04-01
|
| Series: | JMIR Research Protocols |
| Online Access: | https://www.researchprotocols.org/2025/1/e56519 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729660661792768 |
|---|---|
| author | Erlina Burhan Farchan Azzumar Fira Alyssa Gabriella Sinuraya Muhammad Ilham Dhiya Rakasiwi Ihya Akbar Farhan Mubarak Anggit Tresna Rengganis Rizky Abi Rachmadi Hera Afidjati |
| author_facet | Erlina Burhan Farchan Azzumar Fira Alyssa Gabriella Sinuraya Muhammad Ilham Dhiya Rakasiwi Ihya Akbar Farhan Mubarak Anggit Tresna Rengganis Rizky Abi Rachmadi Hera Afidjati |
| author_sort | Erlina Burhan |
| collection | DOAJ |
| description |
BackgroundChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2 are the five common COVID-19 vaccines used in Jakarta. Randomized controlled trials have provided robust evidence of the safety and efficacy profile of these vaccines, but their real-world vaccine effectiveness against symptomatic COVID-19 and deaths in communities with social inequalities and health care constraints remains unclear.
ObjectiveThis study aims to evaluate the real-world effectiveness of these COVID-19 vaccines during the waves associated with the Delta and Omicron variants by analyzing existing electronic health care sources.
MethodsA population-based study with a test-negative case-control design will be used to evaluate COVID-19 vaccine effectiveness in Jakarta, focusing on the Delta and Omicron waves. It includes adults 18 years and older who underwent reverse transcription polymerase chain reaction testing for symptomatic COVID-19, classifying them as cases or controls based on their test results. The analysis will consider multiple COVID-19 vaccines introduced during these periods, with participants categorized by vaccination status. Several potential confounders will be assessed, including demographic factors and comorbidities. Data will be linked from various health datasets, and statistical analyses will be performed to determine vaccine effectiveness and potential waning immunity over time. After data linkage, patients’ identities will be encrypted.
ResultsThe research, funded from 2022 to 2024, involved proposal preparation and ethical review in 2023 and enrollment from early 2024 to July 2024, resulting in about 4 million linked data points. Data analysis is ongoing, with initial results expected for publication in early 2025.
ConclusionsThis study will be the first to evaluate the effectiveness of different types of COVID-19 vaccines (inactivated, viral-vector, and mRNA) used in Jakarta during the pandemic, providing valuable scientific evidence to inform future vaccination strategies in the country.
International Registered Report Identifier (IRRID)DERR1-10.2196/56519 |
| format | Article |
| id | doaj-art-a6f8046d68b8414f941c60a5ca501b16 |
| institution | DOAJ |
| issn | 1929-0748 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Research Protocols |
| spelling | doaj-art-a6f8046d68b8414f941c60a5ca501b162025-08-20T03:09:08ZengJMIR PublicationsJMIR Research Protocols1929-07482025-04-0114e5651910.2196/56519Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care DataErlina Burhanhttps://orcid.org/0000-0002-8115-8293Farchan Azzumarhttps://orcid.org/0009-0007-0327-4399Fira Alyssa Gabriella Sinurayahttps://orcid.org/0000-0002-5935-8870Muhammad Ilham Dhiya Rakasiwihttps://orcid.org/0000-0001-8868-1004Ihya Akbarhttps://orcid.org/0009-0007-9407-982XFarhan Mubarakhttps://orcid.org/0009-0004-5737-7543Anggit Tresna Rengganishttps://orcid.org/0009-0000-2285-9463Rizky Abi Rachmadihttps://orcid.org/0000-0003-4356-1222Hera Afidjatihttps://orcid.org/0009-0007-9748-3545 BackgroundChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2 are the five common COVID-19 vaccines used in Jakarta. Randomized controlled trials have provided robust evidence of the safety and efficacy profile of these vaccines, but their real-world vaccine effectiveness against symptomatic COVID-19 and deaths in communities with social inequalities and health care constraints remains unclear. ObjectiveThis study aims to evaluate the real-world effectiveness of these COVID-19 vaccines during the waves associated with the Delta and Omicron variants by analyzing existing electronic health care sources. MethodsA population-based study with a test-negative case-control design will be used to evaluate COVID-19 vaccine effectiveness in Jakarta, focusing on the Delta and Omicron waves. It includes adults 18 years and older who underwent reverse transcription polymerase chain reaction testing for symptomatic COVID-19, classifying them as cases or controls based on their test results. The analysis will consider multiple COVID-19 vaccines introduced during these periods, with participants categorized by vaccination status. Several potential confounders will be assessed, including demographic factors and comorbidities. Data will be linked from various health datasets, and statistical analyses will be performed to determine vaccine effectiveness and potential waning immunity over time. After data linkage, patients’ identities will be encrypted. ResultsThe research, funded from 2022 to 2024, involved proposal preparation and ethical review in 2023 and enrollment from early 2024 to July 2024, resulting in about 4 million linked data points. Data analysis is ongoing, with initial results expected for publication in early 2025. ConclusionsThis study will be the first to evaluate the effectiveness of different types of COVID-19 vaccines (inactivated, viral-vector, and mRNA) used in Jakarta during the pandemic, providing valuable scientific evidence to inform future vaccination strategies in the country. International Registered Report Identifier (IRRID)DERR1-10.2196/56519https://www.researchprotocols.org/2025/1/e56519 |
| spellingShingle | Erlina Burhan Farchan Azzumar Fira Alyssa Gabriella Sinuraya Muhammad Ilham Dhiya Rakasiwi Ihya Akbar Farhan Mubarak Anggit Tresna Rengganis Rizky Abi Rachmadi Hera Afidjati Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data JMIR Research Protocols |
| title | Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data |
| title_full | Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data |
| title_fullStr | Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data |
| title_full_unstemmed | Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data |
| title_short | Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data |
| title_sort | real world effectiveness of covid 19 vaccines chadox 1s coronavac bbibp corv mrna 1273 and bnt162b2 in jakarta protocol for test negative design of health care data |
| url | https://www.researchprotocols.org/2025/1/e56519 |
| work_keys_str_mv | AT erlinaburhan realworldeffectivenessofcovid19vaccineschadox1scoronavacbbibpcorvmrna1273andbnt162b2injakartaprotocolfortestnegativedesignofhealthcaredata AT farchanazzumar realworldeffectivenessofcovid19vaccineschadox1scoronavacbbibpcorvmrna1273andbnt162b2injakartaprotocolfortestnegativedesignofhealthcaredata AT firaalyssagabriellasinuraya realworldeffectivenessofcovid19vaccineschadox1scoronavacbbibpcorvmrna1273andbnt162b2injakartaprotocolfortestnegativedesignofhealthcaredata AT muhammadilhamdhiyarakasiwi realworldeffectivenessofcovid19vaccineschadox1scoronavacbbibpcorvmrna1273andbnt162b2injakartaprotocolfortestnegativedesignofhealthcaredata AT ihyaakbar realworldeffectivenessofcovid19vaccineschadox1scoronavacbbibpcorvmrna1273andbnt162b2injakartaprotocolfortestnegativedesignofhealthcaredata AT farhanmubarak realworldeffectivenessofcovid19vaccineschadox1scoronavacbbibpcorvmrna1273andbnt162b2injakartaprotocolfortestnegativedesignofhealthcaredata AT anggittresnarengganis realworldeffectivenessofcovid19vaccineschadox1scoronavacbbibpcorvmrna1273andbnt162b2injakartaprotocolfortestnegativedesignofhealthcaredata AT rizkyabirachmadi realworldeffectivenessofcovid19vaccineschadox1scoronavacbbibpcorvmrna1273andbnt162b2injakartaprotocolfortestnegativedesignofhealthcaredata AT heraafidjati realworldeffectivenessofcovid19vaccineschadox1scoronavacbbibpcorvmrna1273andbnt162b2injakartaprotocolfortestnegativedesignofhealthcaredata |